Search

Supernus Pharmaceuticals Inc

Open

SectorGezondheidszorg

42.92 4.02

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

40.67

Max

41.66

Belangrijke statistieken

By Trading Economics

Inkomsten

-56M

-58M

Verkoop

11M

219M

EPS

0.39

Winstmarge

-26.646

Werknemers

778

EBITDA

-50M

-30M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+57.56% upside

Dividenden

By Acuity

Volgende Winsten

3 nov 2026

Marktinformatie

By TradingEconomics

Marktkapitalisatie

-313M

2.4B

Vorige openingsprijs

38.9

Vorige sluitingsprijs

42.92

Nieuwssentiment

By Acuity

50%

50%

134 / 339 Rangschikking in Healthcare

Supernus Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

16 sep 2026, 22:36 UTC

Supernus Pharmaceuticals Inc is declining in after-market hours, remaining significantly below its 20-day moving average and near the lower end of its one-month range.

15 sep 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower, extending an eight-session decline. Broader market sentiment is affected by a significant drop in the NY Empire State Manufacturing Index.

14 sep 2026, 19:36 UTC

Supernus Pharmaceuticals Inc. is trading higher today, despite broader market pressure from rising crude oil prices and geopolitical supply concerns.

11 sep 2026, 20:13 UTC

Supernus Pharmaceuticals Inc. shares rose in after-market trading, reflecting broader market trends amid recent inflation data and speculation of a Federal Reserve interest rate hike.

10 sep 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a five-session decline amid broader market trends following the European Central Bank's interest rate hike.

8 sep 2026, 20:02 UTC

Supernus Pharmaceuticals Inc. shares are lower as the Pharmaceuticals sub-sector faces significant declines, continuing a trend from the past three sessions.

2 sep 2026, 19:36 UTC

Supernus Pharmaceuticals is trading higher Wednesday, despite earlier pulling back from an intraday peak amid broader geopolitical tensions affecting oil prices.

1 sep 2026, 20:09 UTC

Supernus Pharmaceuticals Inc shares are lower today amid increased market volatility and investor concerns over rising oil prices and potential Federal Reserve interest rate hikes.

31 aug 2026, 21:02 UTC

Supernus Pharmaceuticals Inc shares are higher in after-market trading, reflecting a notable rise since Monday's close. No specific news was identified to explain the movement.

28 aug 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are trading lower, continuing a trend of declines amid broader market concerns about inflation and Federal Reserve remarks on price stability.

27 aug 2026, 20:07 UTC

Supernus Pharmaceuticals Inc shares are declining, continuing a downward trend since Wednesday. Broader market conditions may be contributing to this weakness.

26 aug 2026, 20:08 UTC

Supernus Pharmaceuticals Inc shares are lower today, driven by declines in the Pharmaceuticals sub-sector. The stock is trading near its one-month low.

25 aug 2026, 19:16 UTC

Supernus Pharmaceuticals Inc. shares are higher today amid a broader market rally, supported by falling crude oil prices and lower treasury yields.

24 aug 2026, 19:26 UTC

Supernus Pharmaceuticals Inc. shares are lower, continuing a four-session decline amid broader market volatility and geopolitical tensions affecting oil supply.

21 aug 2026, 20:01 UTC

Supernus Pharmaceuticals Inc. shares are lower today, aligning with broader market weakness and finishing at the lowest point observed during the session.

20 aug 2026, 21:01 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, continuing a trend of three consecutive daily declines amid broader market pressures.

18 aug 2026, 19:36 UTC

Supernus Pharmaceuticals Inc is trading higher, maintaining upward momentum since Monday. The stock remains above its 20-day moving average and near a one-month high.

17 aug 2026, 19:26 UTC

News

Supernus Pharmaceuticals Inc is featured in a cautionary analysis from Yahoo Finance, citing below-average sales growth and declining cash flow margin. The stock is roughly flat today.

14 aug 2026, 19:16 UTC

Macro Event

Supernus Pharmaceuticals Inc shares are higher, maintaining momentum since Thursday amid broader market caution following a decline in U.S. retail sales.

13 aug 2026, 19:16 UTC

Supernus Pharmaceuticals Inc shares are lower Thursday, pulling back from an early high. No specific news was identified to explain the movement.

12 aug 2026, 19:51 UTC

Supernus Pharmaceuticals shares are higher amid positive market sentiment following an inflation report and strength in technology stocks.

11 aug 2026, 20:01 UTC

Supernus Pharmaceuticals Inc shares are lower as the Pharmaceuticals sector declines. The stock is trading with unusually high volume today.

10 aug 2026, 22:46 UTC

Supernus Pharmaceuticals Inc shares are lower in after-market hours, reflecting a slight decline since Monday's close amid broader market reassessments of interest rate hikes.

7 aug 2026, 19:31 UTC

Supernus Pharmaceuticals Inc. is trading higher, influenced by an advancing overall market amid positive macroeconomic indicators, despite ongoing geopolitical tensions.

6 aug 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, continuing a decline since Wednesday's close, amid unusually high market volume.

5 aug 2026, 20:03 UTC

Supernus Pharmaceuticals Inc shares are higher Wednesday, driven by high market volume and broader positive sentiment amid declining oil prices and geopolitical optimism.

4 aug 2026, 19:51 UTC

News

Supernus Pharmaceuticals is declining following its merger announcement with Indivior and a quarterly revenue report of $219 million amid a net loss of $58 million.

3 aug 2026, 19:51 UTC

Social Media
News
Event

Supernus Pharmaceuticals announced a merger with Indivior, creating a company with $2.2 billion in revenue. Shares are higher following strong Q2 earnings that beat estimates.

31 jul 2026, 20:03 UTC

Supernus Pharmaceuticals Inc. shares are lower today, reversing from an early gain amid broader market concerns over rising Treasury yields and crude oil prices.

30 jul 2026, 14:33 UTC

Supernus Pharmaceuticals Inc. shares are lower, impacted by weakness in the pharmaceuticals sub-sector. The stock briefly rebounded earlier in the session before declining.

Peer Vergelijking

Prijswijziging

Supernus Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

57.56% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 65.2 USD  57.56%

Hoogste 67 USD

Laagste 63 USD

Gebaseerd op 5 Wall Street-analisten die 12-maands prijsdoelen bieden voor Supernus Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

5 ratings

5

Buy

0

Hold

0

Sell

Sentiment

By Acuity

134 / 339 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Supernus Pharmaceuticals Inc

Supernus Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age. It also offers comprise Qelbree, a novel non-stimulant indicated for the treatment of attention-deficit hyperactivity disorder (ADHD) in adults and pediatric patients 6 years and older; APOKYN for the acute intermittent treatment of hypomobility or off episodes in patients with advanced Parkinson's Disease (PD); XADAGO for treating levodopa/carbidopa in patients with PD experiencing off episodes; MYOBLOC, a Type B toxin product indicated for the treatment of cervical dystonia and sialorrhea in adults; GOCOVRI for the treatment of dyskinesia in patients with PD; and Osmolex ER for the treatment of Parkinson's disease and drug-induced extrapyramidal reaction in adult patients. In addition, the company's product candidates include SPN-830, a late-stage drug/device combination product candidate for the treatment of off episodes in PD patients; SPN-817, a novel first-in-class selective acetylcholinesterase inhibitor, which is in Phase II clinical trials for the treatment of epilepsy; SPN-820, a product candidate in Phase II clinical trials for treating resistant depression; SPN-443, a preclinical product for the treatment of ADHD/CNS; and SPN-446 for narcolepsy and SPN-448 for the treatment of CNS which is in discovery stage. It markets and sells its products through pharmaceutical wholesalers, specialty pharmacies, and distributors. Supernus Pharmaceuticals, Inc. was incorporated in 2005 and is headquartered in Rockville, Maryland.
help-icon Live chat